Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829309 · ClinicalTrials.gov registry record · Phase 1
Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00829309: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00829309 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829309, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study compared the relative bioavailability (rate and extent of absorption) of Pravastatin Sodium Tablets 80 mg by Teva Pharmaceutical Industries, Ltd. with that of Pravachol® Tablets 80 mg by Bristol-Myers Squibb Company following a single oral dose (1 x 80 mg tablet)in healthy adult male subjects administered under non-fasting conditions.
Interventions
- DRUG Pravastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829309
The ClinicalTrials.gov registry entry for NCT00829309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pravastatin is the first listed.
NCT00829309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829309 about?
NCT00829309 is a clinical study titled "Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions". This study compared the relative bioavailability (rate and extent of absorption) of Pravastatin Sodium Tablets 80 mg by Teva Pharmaceutical Industries, Ltd. with that of Pravachol® Tablets 80 mg by Bristol-Myers Squibb Company following a single oral dose (1 x 80 mg tablet)in healthy adult male subj...
What is the current status of trial NCT00829309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2005-03. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00829309?
The interventions under investigation include: Pravastatin (DRUG).
Who is sponsoring clinical trial NCT00829309?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.